On Friday, CytRx Corporation (NASDAQ:CYTR)’s shares inclined 1.97% to $4.15.
CytRx Corporation (CYTR) declared positive updated results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer. The open-label, multisite trial is designed to investigate the preliminary efficacy and safety of aldoxorubicin in patients whose tumors have progressed following prior treatment with surgery, radiation and temozolomide.
Study subjects (n=18) have received between 1 and 14 cycles of aldoxorubicin, with 4 subjects ongoing to receive aldoxorubicin treatment. Subjects received either 350 mg/m2 (260 mg/m2 doxorubicin equivalent) (n=6) or 250 mg/m2 (185 mg/m2 doxorubicin equivalent) (n=12) of aldoxorubicin intravenously on Day 1, and every 21 days thereafter until discontinuation. Notably, 2 subjects (11%) diagnosed with tumor progression following aldoxorubicin treatment (1 and 5 cycles, respectively) demonstrated no microscopic evidence of tumor tissue, a pathological complete response, when tissue was examined after resection. Fourteen of 18 subjects suspended aldoxorubicin treatment, although there is a noteworthypossibility that some of the patients practiced pseudo-progression. Pseudo-progression refers to post-treatment imaging changes in the tumor where the tumor appears larger contrast to the pre-treatment baseline images. These changes can be misleading in that the tumor appears to get worse (true progression), when in fact the changes may be the result of tumor destruction and related swelling around the tumor bed. Following discontinuation of aldoxorubicin treatment, 10 of 14 subjects received treatment with bevacizumab (Avastin®) for 1 to 14 cycles. Deaths have occurred in only 4 of 18 subjects (22%) to date, with survival duration so far of up to 10 plus months.
CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi’s sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors.
Scientific Games Corp (NASDAQ:SGMS)’s shares gained 1.81% to $16.29.
Scientific Games Corp (SGMS) declared that Penn National Gaming’s new Plainridge Park Casino, Massachusetts’ first casino, located in Plainville, Mass., will open with a broad suite of the Company’s systems and games solutions to drive casino revenue and operating efficiencies and empower an exceptional gaming experience for players.
Scientific Games hit several noteworthy milestones with the Penn National Gaming agreement. The Company’s Bally, WMS, and Shuffle Master-branded games will account for 44 percent floor share of new gaming devices, and Plainridge will be the first casino in the country to implement a Bally play-administration system for responsible gaming, which is a voluntary option for customers and is required by the Massachusetts Gaming Commission.
Gavin Isaacs, President and Chief Executive Officer, Scientific Games, said “We are honored and excited to expand our long-standing and thriving partnership with Penn National by providing Plainridge Park Casino such a broad portfolio of our products representing our popular Bally, WMS, and Shuffle Master product brands across systems and games.
Scientific Games Corporation develops technology-based products and services, and associated content for the gaming and lottery industries worldwide. The company operates through three segments: Gaming, Lottery, and Interactive. The Gaming segment offers gaming machines, conversion kits, automatic card shufflers, roulette chip sorters, and spare parts; leases gaming machines, automatic card shufflers, roulette chip sorters, and server-based gaming systems and content; and licenses proprietary table game content. This segment also provides video lottery central monitoring and control systems and networks for gaming regulators; and casino-administration technology solutions and systems. This segment serves commercial, tribal, and governmental gaming operators.
At the end of Friday’s trade, Royal Bank of Canada (NYSE:RY)‘s shares dipped -0.02% to $63.95.
Royal Bank of Canada (RY) declared it has closed its domestic public offering of Non-Cumulative, Preferred Shares Series BH. Royal Bank of Canada issued 6 million Preferred Shares Series BH at a price of $25 per share to raise gross proceeds of $150 million .
The offering was underwritten by a syndicate led by RBC Capital Markets. The Preferred Shares Series BH will commence trading on the Toronto Stock Exchange recently under the ticker symbol RY.PR.N.
The Preferred Shares Series BH were issued under a prospectus supplement dated May 29, 2015 to the bank’s short form base shelf prospectus dated December 20, 2013 .
The Preferred Shares Series BH have not been and will not be registered in the United States under the United States Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state of the United States and may not be offered, sold or delivered, directly or indirectly in the United States or to, or for the account or benefit of, a “U.S. person” (as defined in Regulation S under the Securities Act) absent registration under the Securities Act or an applicable exemption from such registration requirements. This press release does not constitute an offer to sell or a solicitation to buy securities in the United States or in any other jurisdiction where such offer or solicitation would be unlawful.
Royal Bank of Canada, together with its auxiliaries, operates as a diversified financial service company worldwide. The company operates through five segments: Personal & Commercial Banking, Wealth Administration, Insurance, Investor & Treasury Services, and Capital Markets.
CBL & Associates Properties, Inc. (NYSE:CBL), ended its Friday’s trading session with -1.83% loss, and closed at $17.13.
CBL & Associates Properties, Inc. (CBL) declared that it will provide an online audio simulcast of the presentation given by its President and Chief Executive Officer, Stephen D. Lebovitz, to the investment community at REITWeek 2015: NAREIT’s Investor Forum in New York City. The presentation will take place on Tuesday, June 9, 2015, at 8:45 a.m. Eastern Time.
CBL & Associates Properties, Inc. is a public real estate investment trust. It engages in acquisition, development, and administration of properties. The fund invests in the real estate markets of United States. Its portfolio comprises of enclosed malls and open-air centers. CBL & Associates Properties is based in Oak Brook, Illinois. CBL & Associates Properties was founded in 1978 and is based in Chattanooga, Tennessee with additional offices in Waltham, Massachusetts; Chesterfield, Missouri; and Irving, Texas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
